contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Initiativtager Pharma er aktiv inden for bioteknologi. I dag er det primære forretningsfokus på udvikling af lægemiddelkandidater, der bruges i behandlingen af erektil dysfunktion hos mænd. Virksomheden har i øjeblikket lægemidler under klinisk fasetestning til patienter, der ikke reagerer på PDE5i-lægemidler. Initiativtager Pharma er skabt via et spin-off fra Saniona og har i dag hovedsæde i Åbyhøj.

Initiator Pharma

Business highlights in Q4 2025In November the Company announced that its Clinical Trial Application (CTA) for a planned Phase IIa clinical proof-of-concept study in women with vulvodynia had...

<div class="mfn-preamble"><p><strong>Business highlights in Q4 2025</strong></p></div><div class="mfn-body"><ul><li>In November the Company announced that its Clinical Trial Application (CTA) for a planned Phase IIa clinical proof-of-concept study in women with vulvodynia had been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and a local ethics committee.</li><li>In December the Company initiated patient enrollment in its Phase IIa clinical proof-of-concept study evaluating pudafensine in women suffering from vulvodynia. Dosing of the first patients is expected to begin in January 2026, and completion of the study is projected by the end of 2026.</li></ul><p><strong>Business highlights after this reporting period</strong></p><ul><li>The European FSD patent (EP4551221B1) was granted 18 Feb 2026.</li></ul><p><strong>Financial Highlights</strong></p><table><tbody><tr><td valign="middle" rowspan="1" colspan="1"><strong>Fourth Quarter (2025-10-01 – 2025-12-31)</strong></td></tr><tr><td valign="middle" rowspan="1" colspan="1">Net revenue were KDKK 0 (0)</td></tr><tr><td valign="middle" rowspan="1" colspan="1">Operating loss, EBIT was KDKK -6,966 (-2,701)</td></tr><tr><td valign="middle" rowspan="1" colspan="1">Earnings per share before and after dilution was DKK -0.04 (-0.02)</td></tr><tr><td valign="middle" rowspan="1" colspan="1">Cash: KDKK 26,245 (13,371)</td></tr><tr><td valign="middle" rowspan="1" colspan="1">Solidity: 90% (97%)</td></tr></tbody></table><table><tbody><tr><td valign="middle" rowspan="1" colspan="1"><strong>Full year 2025 (2025-01-01 – 2025-12-31)</strong></td></tr><tr><td valign="middle" rowspan="1" colspan="1">Net revenues were TDKK 0 (0)</td></tr><tr><td valign="middle" rowspan="1" colspan="1">Operating loss, EBIT was TDKK -17,781 (-14,502)</td></tr><tr><td valign="middle" rowspan="1" colspan="1">Earnings per share before and after dilution was DKK –0.20 (-0.23)</td></tr></tbody></table><p><em>Solidity: equity divided by assets.</em></p><p>The Board of Directors have decided that interim reports will be published in English only.</p><p><strong>Link to the full report</strong><br><a rel="noopener" href="https://www.initiatorpharma.com/en/investors/reports-and-presentations/">https://www.initiatorpharma.com/en/investors/reports-and-presentations/</a></p></div><div class="mfn-footer mfn-contacts mfn-8e6161468890"><p><strong class="mfn-heading-1">For additional information about Initiator Pharma, please contact:</strong></p><hr><p>Claus Elsborg Olesen, CEO<br>Telephone: +45 6126 0035<br>E-mail:&nbsp;<a rel="noopener" href="mailto:ceo@initiatorpharma.com">ceo@initiatorpharma.com</a></p></div><div class="mfn-footer mfn-about mfn-cdb0015b163c"><p><strong class="mfn-heading-1">About Initiator Pharma</strong></p><hr><p>Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of two clinical stage assets – pudafensine and IP2018 – and one preclinical asset. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED. With IP2018 the company has reported positive, statistically significant, and dose-dependent clinical observations related to efficacy in psychogenic erectile dysfunction (ED) in a Phase IIa clinical trial of IP2018 in patients with mild to moderate ED.<br>&nbsp;<br>Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye Sweden AB is the company’s Certified Adviser. For more information, please visit <a rel="noopener" href="http://www.initiatorpharma.com.">www.initiatorpharma.com.</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/6efde9fa-32ad-4128-80df-40d15932c352/init-2025-q4-final.pdf" class="mfn-primary">INIT 2025 Q4 Final</a></p></div>